U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

Q2 2025 Management View Paul Hudson, CEO, reported "another strong quarter with double-digit sales growth," attributing the ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

President Donald Trump has given leading pharma manufacturers a 60-day deadline to come up with a most favoured nation (MFN) ...

European shares dipped to a more than one-week low as investors reacted to corporate reports and U.S. tariffs impacting sectors like automotives and beverages. Companies like Ferrari and Sanofi saw ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and has been filed with the French market regulator Autorité des ...

July 7 – With a 90-day negotiating period on country-specific US tariffs is set to expire on July 9, Trump enacts a multitude ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...